N-苄基-2-氯嘧啶-4-胺 | 71406-74-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-苄基-2-氯嘧啶-4-胺
• 英文名称: N-benzyl-2-chloropyrimidin-4-amine
• 英文别名: benzyl(2-chloropyrimidin-4-yl)amine
• CAS: 71406-74-1
• 化学式: C₁₁H₁₀ClN₃
• 分子量: 219.673
• InChiKey: QWRADTLPANSRDT-UHFFFAOYSA-N

物化性质

• 沸点：
  407.7±20.0 °C(Predicted)
• 密度：
  1.307±0.06 g/cm3(Predicted)
• 溶解度：
  >33 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-苄基-2-氯嘧啶-4-胺 在 间氯过氧苯甲酸 作用下， 以 1,4-二氧六环 、 正丁醇 为溶剂， 反应 3.08h， 生成 4-[4-(benzylamino)pyrimidin-2-yl]thiomorpholine-1-oxide
  参考文献：
  名称：

  Design, synthesis and structure–activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: Dual activity as cholinesterase and Aβ-aggregation inhibitors

  摘要：

  A novel class of 2,4-disubstituted pyrimidines (7a-u, 8a-f, 9a-e) that possess substituents with varying steric and electronic properties at the C-2 and C-4 positions, were designed, synthesized and evaluated as dual cholinesterase and amyloid-beta (A beta)-aggregation inhibitors. In vitro screening identified N-(naphth-1-ylmethyl)-2-(pyrrolidin-1-yl)pyrimidin-4-amine (9a) as the most potent AChE inhibitor (IC50 = 5.5 mu M). Among this class of compounds, 2-(4-methylpiperidin-1-yl)-N-(naphth-1-ylmethyl) pyrimidin-4-amine (9e) was identified as the most potent and selective BuChE inhibitor (IC50 = 2.2 mu M, selectivity index = 11.7) and was about 5.7-fold more potent compared to the commercial, approved reference drug galanthamine (BuChE IC50 = 12.6 mu M). In addition, the selective AChE inhibitor N-benzyl-2-(4-methylpiperazin-1-yl)pyrimidin-4-amine (7d), exhibited good inhibition of hAChE-induced aggregation of A beta(1-40) fibrils (59% inhibition). Furthermore, molecular modeling studies indicate that a central pyrimidine ring serves as a suitable template to develop dual inhibitors of cholinesterase and AChE-induced A beta aggregation thereby targeting multiple pathological routes in AD. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.02.030
• 作为产物：
  描述：

  2,4-二氯嘧啶 、 苄胺 在 三乙胺 作用下， 以 乙醇 为溶剂， 以76%的产率得到N-苄基-2-氯嘧啶-4-胺
  参考文献：
  名称：

  作为VEGFR-2酪氨酸激酶抑制剂的嘧啶基衍生物的设计，合成和生物学评估

  摘要：

  血管内皮生长因子受体2（VEGFR-2）在肿瘤血管生成中起着至关重要的作用，而抑制VEGFR-2信号通路已经成为癌症治疗的一种有吸引力的方法。在这项研究中，设计了一种新型的基于嘧啶的衍生物7j作为前导化合物，合成了三组有效的VEGFR-2抑制剂，并针对A549和HepG2细胞系进行了生物学评估。与Pazopanib（IC 50）相比，化合物7d，9s和13n对A549细胞的IC 50为9.19至13.17μM，对HepG2细胞的IC 50为11.94至18.21μM。 = 21.18和36.66μM）。另外，进行了分子对接研究以研究目标化合物与VEGFR-2之间的结合能力和结合方式。

  DOI：

  10.1016/j.bioorg.2018.04.005

文献信息

• Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases
  作者：Luc J. Farmer、Mark W. Ledeboer、Thomas Hoock、Michael J. Arnost、Randy S. Bethiel、Youssef L. Bennani、James J. Black、Christopher L. Brummel、Ananthsrinivas Chakilam、Warren A. Dorsch、Bin Fan、John E. Cochran、Summer Halas、Edmund M. Harrington、James K. Hogan、David Howe、Hui Huang、Dylan H. Jacobs、Leena M. Laitinen、Shengkai Liao、Sudipta Mahajan、Valerie Marone、Gabriel Martinez-Botella、Pamela McCarthy、David Messersmith、Mark Namchuk、Luke Oh、Marina S. Penney、Albert C. Pierce、Scott A. Raybuck、Arthur Rugg、Francesco G. Salituro、Kumkum Saxena、Dean Shannon、Dina Shlyakter、Lora Swenson、Shi-Kai Tian、Christopher Town、Jian Wang、Tiansheng Wang、M. Woods Wannamaker、Raymond J. Winquist、Harmon J. Zuccola

  DOI：10.1021/acs.jmedchem.5b00301

  日期：2015.9.24

  signaling kinase in immune cells, and identified multiple scaffolds showing good inhibitory activity for this kinase. A particular scaffold of interest, the 1H-pyrrolo[2,3-b]pyridine series (7-azaindoles), was selected for further optimization in part on the basis of binding affinity (Ki) as well as on the basis of cellular potency. Optimization of this chemical series led to the identification of VX-509

  尽管存在几种治疗选择，但是仍然需要针对多种自身免疫疾病的更有效，安全和方便的治疗方法。靶向Janus酪氨酸激酶（JAKs）在细胞信号传导反应中起着重要作用，并且可以促进与疾病相关的异常免疫功能，它已成为开发新型自身免疫性疾病疗法的一种新颖且有吸引力的方法。我们针对免疫细胞中的关键信号激酶JAK3筛选了我们的化合物文库，并鉴定了多个支架对该支架表现出良好的抑制活性。选择了特定的目标支架1 H-吡咯并[2,3- b ]吡啶系列（7-氮杂吲哚），部分基于结合亲和力（K i）以及细胞效能的基础上。该化学系列的优化导致鉴定出一种新型，有效和选择性的JAK3抑制剂VX-509（地加罗非尼），与大鼠移植模型（HvG）相比，它在大鼠宿主体内显示出良好的疗效。基于这些发现，看来VX-509为治疗多种自身免疫性疾病提供了潜力。
• [EN] 2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES<br/>[FR] 2-AMINOPYRIMIDINE ET 2-AMINOPYRIDINE-4-CARBAMATES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES AUTO-IMMUNES
  申请人：AMGEN INC

  公开号：WO2005009978A1

  公开（公告）日：2005-02-03

  The present invention relates to pyrimidine or pyridine carbamate compounds having the general Formula (1) and pharmaceutically acceptable salts or derivatives thereof. Also included are methods of treatment of various diseases and conditions, including inflammation, inhibition of T cell activation and proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma, thymoma, just to name a few, in a mammal, the methods comprising administering a therapeutically-effective amount a compound of Formula I, or a salt or derivative form thereof, as described above.

  本发明涉及具有通用式（1）的嘧啶或吡啶羰酸酯化合物及其药用可接受的盐或衍生物。还包括治疗各种疾病和症状的方法，包括炎症、抑制T细胞激活和增殖、关节炎、器官移植、缺血或再灌注损伤、心肌梗死、中风、多发性硬化、炎症性肠病、克罗恩病、狼疮、过敏、1型糖尿病、牛皮癣、皮炎、桥本氏甲状腺炎、干燥综合征、自身免疫性甲状腺功能亢进症、艾迪生病、自身免疫疾病、肾小球肾炎、过敏性疾病、哮喘、花粉症、湿疹、癌症、结肠癌、胸腺瘤等，在哺乳动物中的方法，包括给予通用式I的化合物的治疗有效量，或如上所述的盐或衍生物形式。
• [EN] SUBSTITUTED AZAHETEROCYCLES FOR THE TREATMENT OF CANCER<br/>[FR] AZAHÉTÉROCYCLES SUBSTITUÉS POUR LE TRAITEMENT DU CANCER
  申请人：MERCK PATENT GMBH

  公开号：WO2013004332A1

  公开（公告）日：2013-01-10

  The invention provides novel substituted azaheterocyclic compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.

  该发明提供了根据式(I)提供的新型取代的氮杂杂环化合物，其制备和用于治疗高增殖性疾病，如癌症。
• HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20170304278A1

  公开（公告）日：2017-10-26

  The present application relates to novel heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.

  本申请涉及新颖的杂环芳基取代的咪唑[1,2-a]吡啶化合物，以及其制备方法，单独或组合使用于治疗和/或预防疾病，以及用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• Design, synthesis and structure-activity relationship studies of a focused library of pyrimidine moiety with anti-proliferative and anti-metastasis activities in triple negative breast cancer
  作者：Dahong Yao、Yuxin Zhou、Lingjuan Zhu、Liang Ouyang、Jin Zhang、Yingnan Jiang、Yuqian Zhao、Dejuan Sun、Shilin Yang、Yang Yu、Jinhui Wang

  DOI：10.1016/j.ejmech.2017.08.067

  日期：2017.11

  characterized by high aggression, poor prognosis, and lack of targeted therapies. In this study, based on the structural features of type II kinase inhibitors, we designed and synthesized a focused library of 41 pyrimidine derivatives possessing potent anti-proliferation activity, Y29 showed the most potent activity against MDA-MB-231 cells. Subsequently, we carried out target prediction, homology modeling

  三阴性乳腺癌（TNBC）是一种临床难题，具有独特的临床和病理学特征，其特征是攻击性高，预后差和缺乏靶向治疗。在这项研究中，基于II型激酶抑制剂的结构特征，我们设计并合成了具有41个嘧啶衍生物的聚焦文库，这些衍生物具有强大的抗增殖活性，Y29对MDA-MB-231细胞的活性最强。随后，我们进行了目标预测，同源性建模，分子对接，动力学模拟和酶活性的测定。结果表明PDGFR-β是其潜在的靶标。